144 related articles for article (PubMed ID: 12213292)
21. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.
Heilberg IP; Hernandez E; Alonzo E; Valera R; Ferreira LG; Gomes SA; Bellorin-Font E; Weisinger JR
Ren Fail; 2005; 27(2):155-61. PubMed ID: 15807179
[TBL] [Abstract][Full Text] [Related]
22. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Hadji P; Ziller M; Kieback DG; Menschik T; Kalder M; Kuck J; Hasenburg A
Breast; 2009 Jun; 18(3):159-64. PubMed ID: 19364653
[TBL] [Abstract][Full Text] [Related]
23. A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density.
Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Mijares V; González-Macías J
Eur J Endocrinol; 2006 Jul; 155(1):53-9. PubMed ID: 16793950
[TBL] [Abstract][Full Text] [Related]
24. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
[TBL] [Abstract][Full Text] [Related]
25. No major effect of estrogen receptor gene polymorphisms on bone mineral density or bone loss in postmenopausal Danish women.
Bagger YZ; Jørgensen HL; Heegaard AM; Bayer L; Hansen L; Hassager C
Bone; 2000 Feb; 26(2):111-6. PubMed ID: 10678404
[TBL] [Abstract][Full Text] [Related]
26. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk.
van Meurs JB; Schuit SC; Weel AE; van der Klift M; Bergink AP; Arp PP; Colin EM; Fang Y; Hofman A; van Duijn CM; van Leeuwen JP; Pols HA; Uitterlinden AG
Hum Mol Genet; 2003 Jul; 12(14):1745-54. PubMed ID: 12837697
[TBL] [Abstract][Full Text] [Related]
27. Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.
Yim CH; Choi JT; Choi HA; Kang YS; Moon IG; Yoon HK; Han IK; Kang DH; Han KO
J Bone Miner Metab; 2005; 23(5):395-400. PubMed ID: 16133690
[TBL] [Abstract][Full Text] [Related]
28. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
29. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor gene polymorphisms in a group of postmenopausal Turkish women: association with bone mineral density.
Yavuz DG; Yoldemir T; Ozaltun K; Erenus M
Climacteric; 2012 Aug; 15(4):368-73. PubMed ID: 22141363
[TBL] [Abstract][Full Text] [Related]
31. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
[TBL] [Abstract][Full Text] [Related]
32. Non-association of estrogen receptor genotypes with bone mineral density and bone turnover in Korean pre-, peri-, and postmenopausal women.
Han K; Choi J; Moon I; Yoon H; Han I; Min H; Kim Y; Choi Y
Osteoporos Int; 1999; 9(4):290-5. PubMed ID: 10550445
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen.
Kobayashi N; Fujino T; Shirogane T; Furuta I; Kobamatsu Y; Yaegashi M; Sakuragi N; Fujimoto S
Maturitas; 2002 Mar; 41(3):193-201. PubMed ID: 11886765
[TBL] [Abstract][Full Text] [Related]
34. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density.
Napoli N; Villareal DT; Mumm S; Halstead L; Sheikh S; Cagaanan M; Rini GB; Armamento-Villareal R
J Bone Miner Res; 2005 Feb; 20(2):232-9. PubMed ID: 15647817
[TBL] [Abstract][Full Text] [Related]
35. The Sp1 COLIA1 gene polymorphism, and not vitamin D receptor or estrogen receptor gene polymorphisms, determines bone mineral density in postmenopausal Greek women.
Efstathiadou Z; Kranas V; Ioannidis JP; Georgiou I; Tsatsoulis A
Osteoporos Int; 2001; 12(4):326-31. PubMed ID: 11420783
[TBL] [Abstract][Full Text] [Related]
36. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
38. CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.
Drummond FJ; Mackrill JJ; O'sullivan K; Daly M; Shanahan F; Molloy MG
J Bone Miner Metab; 2006; 24(1):28-35. PubMed ID: 16369895
[TBL] [Abstract][Full Text] [Related]
39. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
40. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
Henry NL; Nguyen A; Azzouz F; Li L; Robarge J; Philips S; Cao D; Skaar TC; Rae JM; Storniolo AM; Flockhart DA; Hayes DF; Stearns V
Br J Cancer; 2010 Jan; 102(2):294-300. PubMed ID: 19953095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
